Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Labetalol dosing patterns for blood pressure management in acute cerebral hemorrhage and spontaneous subarachnoid hemorrhage
TCTR20200501001Phase 4Not yet recruiting
- Sponsor
- Great Eastern Drug Co., Ltd.
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of labetalol in intracerebral hemorrhage (ICH), subarachnoid hemorrhage (SAH), hypertension (HTN), sponsored by Great Eastern Drug Co., Ltd.. Planned start Jun 2020; status: not yet recruiting.
02
Drugs
labetalol
03
Conditions
intracerebral hemorrhage (ICH)subarachnoid hemorrhage (SAH)hypertension (HTN)
Beyond the preview
Go deeper on TCTR20200501001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20200501001.